Together, these results suggest that dexamethasone resistance in BCP-ALL may be related to active signaling in the PI3K/mTOR and MEK/ERK pathways and dasatinib may best target this signaling resulting in increased apoptosis of dexamethasone-resistant cells. This evidence concerns the gene MAP2K7 and acute lymphoblastic leukemia.